Details for Patent: 10,695,339
✉ Email this page to a colleague
Which drugs does patent 10,695,339 protect, and when does it expire?
Patent 10,695,339 protects COBENFY and is included in one NDA.
This patent has eighteen patent family members in nine countries.
Drugs Protected by US Patent 10,695,339
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-001 | Sep 26, 2024 | RX | Yes | No | 10,695,339 | ⤷ Subscribe | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Subscribe | ||||
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-002 | Sep 26, 2024 | RX | Yes | No | 10,695,339 | ⤷ Subscribe | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Subscribe | ||||
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-003 | Sep 26, 2024 | RX | Yes | Yes | 10,695,339 | ⤷ Subscribe | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,695,339
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2804215 | ⤷ Subscribe | |||
| Denmark | 3061821 | ⤷ Subscribe | |||
| European Patent Office | 2456868 | ⤷ Subscribe | |||
| European Patent Office | 3061821 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
